Relationship of Serum Transferrin Levels to Overall Survival in Cancer Patients: Findings from a Multi-Center Cohort Analysis
-
By
-
Qianqian Zhao
-
Kai Sun
-
Xiaoxiao Wu
-
Fangqi Shen
-
Xi Chen
-
Chunhua Song
-
Xiaolin Wang
-
Hongxia Xu
-
Minghua Cong
-
Hanping Shi
-
Pingping Jia
-
January 26, 2026
-
Clinical Scorecard: Relationship of Serum Transferrin Levels to Overall Survival in Cancer Patients: Findings from a Multi-Center Cohort Analysis
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Cancer patients aged 18 and older with confirmed malignant tumors, including specific types like esophageal and head and neck cancers. |
| Care Setting | |
Key Highlights
- Transferrin levels correlate with nutritional status and survival outcomes in cancer patients.
- Low transferrin levels are linked to poor prognosis and increased risk of malnutrition.
- Transferrin serves as a negative acute-phase protein affected by systemic inflammation, impacting immune response.
Guideline-Based Recommendations
Diagnosis
- Assess transferrin levels to evaluate nutritional status and prognosis in cancer patients, with specific thresholds.
Management
- Consider transferrin levels in treatment planning and nutritional interventions for cancer patients, particularly in high-risk groups.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Transferrin can identify malnutrition even when other markers like albumin are normal, influencing treatment decisions.
Clinical Best Practices
- Incorporate transferrin measurement in routine assessments for cancer patients, ideally every 1-3 months.
References
